Related Experiment Video

Updated: May 13, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Therapeutic targets in triple negative breast cancer

Sandra A O'Toole1, Jane M Beith, Ewan K A Millar

  • 1Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. Sandra.O’Toole@sswahs.nsw.gov.au

Journal of Clinical Pathology
|February 26, 2013
PubMed

Insights

Triple negative breast cancer (TNBC) has a poor prognosis with limited treatment options. This review explores novel therapeutic targets, including developmental pathways, to improve outcomes for TNBC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer outcomes have improved, but triple negative breast cancer (TNBC) remains challenging.
  • TNBC lacks expression of oestrogen, progesterone, and HER2 receptors, leading to a poor prognosis.
  • Recurrent TNBC often shows limited response to chemotherapy, highlighting an unmet clinical need.

Purpose of the Study:

  • To review promising therapeutic targets for triple negative breast cancer.
  • To highlight the role of developmental signalling pathways in TNBC pathogenesis.
  • To discuss emerging therapeutic strategies targeting these pathways.

Main Methods:

  • Review of recent sequencing technologies and apoptosis studies.
  • Analysis of evidence implicating Wnt/β-catenin, NOTCH, and Hedgehog pathways in TNBC.
  • Examination of preclinical and early clinical trial data for pathway inhibitors.

Main Results:

  • New sequencing and apoptosis research have identified potential therapeutic targets.
  • Developmental signalling pathways (Wnt/β-catenin, NOTCH, Hedgehog) are crucial in TNBC progression.
  • Inhibitors targeting these pathways show promise in preclinical and early clinical studies.

Conclusions:

  • There is an urgent need for new therapeutic targets for TNBC.
  • Targeting developmental signalling pathways represents a promising strategy.
  • Further research and clinical trials are essential to improve TNBC patient outcomes.
Keywords:
BREAST CANCERBREAST PATHOLOGYCANCER RESEARCH

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: